Neurological outcome of long-term glioblastoma survivors

Abstract

Extended survival of 3 or more years is rare in patients with glioblastoma (GBM) but is becoming more common. Clinical outcome has not been well studied. We reviewed GBM patients at Memorial Sloan-Kettering Cancer Center between 2001 and 2003 who were seen for two or more visits. Patient characteristics and long-term clinical outcomes were reviewed for patients who had survived 3 or more years following diagnosis. Thirty-nine (11%) of 352 GBM patients were identified as long-term survivors. Median survival was 9.15 years (range: 3-18 years). Median age was 47 years (range: 16-69); 13% were 65 years or older. Median KPS was 90 (range: 50-100). One long-term survivor underwent biopsy alone; 19 patients each had either complete or subtotal resection. All received focal radiotherapy (RT) with a median dose of 5940 cGy; 18% received concurrent temozolomide. Adjuvant chemotherapy was administered to 35 (90%). Twelve patients (31%) remained in continuous remission. Twenty-seven had tumor progression a median of 29.2 months after diagnosis (range: 1.2-167 months); 18 had multiple relapses. Median KPS at last follow-up was 70 (range: 40-100); 85% of long-term survivors had at least one significant neurologic deficit. Eleven (28%) had clinically significant RT-induced leukoencephalopathy, 9 (23%) developed RT necrosis and 9 (23%) treatment-related strokes. Treatment-related complications occurred a median of 2.7 years from diagnosis (range: 0.9-11.5 years). Long-term survivors remain rare, but are found across all age groups despite multiple recurrences; clinically significant delayed complications of treatment are common.

Screening children with NF1 for optic pathway glioma – Yes

“…11 This is not a routine practice in our unit and generally in the NHS. To inform the parents of a child with NF1 that a 'brain tumour' has been found but no treatment is going to be given can be challenging news to cope with.…”

Anti-Angiogenic Therapy for Malignant Glioma: Insights and Future Directions

“…Furthermore, Hottinger and colleagues found that 85 percent of long-term survivors of GBM had at least one significant neurological deficit leading to a decline of the median Karnofsy Performance Scale (KPS) value from that at the time of initial diagnosis (from 90 to 70). This decline ultimately results in impaired day-today function (Hottinger, Yoon et al 2009). …”

From survival to survivorship: late side effects become an issue in high-grade glioma

“…Unfortunately the study had two limitations: firstly, due to dwindling numbers, only HRQOL data from the first year of follow-up was analyzed; secondly, neurocognitive function was not formally tested during follow-up. However, there is some preliminary evidence that glioblastoma patients who survive for more than 3 years may fare less well, with 85% having at least one significant neurologic deficit [31].…”